alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
1.'

ABELARDO G- GONZALEZ

Appellant

vsIHE STATE OF TEXAS

A^^lle

IN THE FOORTO COnRT

OF APPraLS

San Antoino. Tevas

1622682 §

§

§

§

§

§

§

COA No. 04-15-00529-CR

04-15-00530-CR

04-15

MOTION FOR EXTENSION OF TIME TO FILE

MOTION FOR REHEARING / RECONSIDERATION 2

TO THE HONORABLE JUDGE"S OF SAID COURT:

Now Coraes ABELARDO G. GONZALEZ, PRO SE. aad moves the court in

the above menticn cause's files in haste on 11-08-2105 this motion for a

extension of time to file a motion for rehearinu / reconsideration under TRAP

49-7 on a ORDER OF DISMISSAL for lack of jurisdiction entered on Oct- 26- 2015

and [Ojnly received by aptjellat cn Itov- 06 . 2015-

(1) This is appellant FIRST motion for a extension of time.

(2) The deadline to file the motion for reheariny / reconsideration is Nov.

12, 2015.

(3) Appellant [0]nly received the dimissal ORCER on Nov. 06- 2015 at the

. T-D-C-J. C. T. TERRELL UNIT on NOV- 06. 2015 (FRIDAY ) SEE EXHIBIT (A)

attached•

[Tjhis unexplain delay of 9 days has txrejudiced appellant since the C-T.

Tterrell law library is CLOSED on Sunday's and Monday's and on Saturday

the 7th of Nov. aj^ellant only at 15 min. of the TWO hour session since

he was pulled out of session bv Syt- Sharp.

Due to the above appellant has not adeuuate reviewed the case law cited

in the ORDER, and therefore can not adeuuately file a meaninyfull, proper

motion for rehearinu / reconsideration-

(4) Appellant respectfullv ask fr a 30 DAY extension added f>"an Nov. 12. 2015

which the new deadline to file would be IDec. 12. 2015.

PRAYER

Appellant prav's this honorable court GRANT this motion.

Attaclnient to this motion

is Ex. (a) small slip:

GRIG. EXXUMENi' (Mailrocm slip)

DO NOT OVER LOOK<<<<<<

Respectfully a^bmitted

Abeiardo G. 'Gonzalez 1622682-

C.T. Terrell B-3-40

1300 P.M. 655

Rosharon- Texas 77583

Appellant / pro-se

Pl/2
NOTIFICATION E BY MAIL ROOM

Inmate Name

Inmate No.

/ mecKi

(Daleand Time)

^regarding the following matter:

Questionable Correspondence

Questionable Publication

Package

Yi Legal, Special, or Media Correspondence ( Other j /

Inmate's Signatun

Notifying

Officer's Sign;

Original—R( ^iiyiiiai—11 lu upiit mall room. d i i ^

Copy—Give completed copy to inmate. hibij,.

/\

//5-/S

room

152 (NRD)

EXHIBIT (A) Motion for extension of time to file motion for rehearitKj / reconsi'^'^rtion

on 04-15-00529-CR / 04-15-n00530-eR / 04-15-00530-eR

Elf. A

P2/:
Abeidfdo Gonzalez 1622682

C.T. Terrell B-3-40

1300 F.M. 655

Rosharoi/ Texas 77583

v>_-- •

&-•—

IdCRo

Qi-^

5z

U9

o

CM

Oz:

CM

LEGAL MAIL

H'Oiji'TOf'5 T5'>.

:C& MOV 2015PM 5 t

CLERK OP THE COURT

Fo: the Fourth Cburt of Aopeals

Cadena-Reeves Justice Coiter

300 Dolorosa SUITE 3200

San Antonio/ Texas 78205-3037
<PAGE>


                                BASE TEN SYSTEMS, INC.
                                      EXHIBIT 21

SUBSIDIARIES OF REGISTRANT


The following are wholly-owned subsidiaries of the Registrant:


                                                           STATE OR JURISDICTION
                        NAME                                 OR ORGANIZATION
--------------------------------------------------------------------------------
Base Ten Aerospace and Communications, Inc.                  New Jersey (a)

Base Ten Software, Inc.                                      New Jersey (a)

Base Ten Systems, Ltd.                                       United Kingdom (a)

Base Ten of Canada, Ltd.                                     Canada (b)

Base Ten Investment, Co.                                     Delaware (b)

Base Ten International Sales, Ltd.                           Jamaica (a)

Base Ten Software, Ltd.                                      Ireland (a)
--------------------------------------------------------------------------------
(a) Financial statements included in Consolidated Financial Statements of
Registrant
(b) Dormant
No. 07-15-00209-CV

In re Steven Edward Boyd, Relator §

§

§

§

Original Proceeding

July 10, 2015

Opinion by Justice Pirtle

J U D G M E N T

Pursuant to the opinion of the Court dated July 10, 2015, it is ordered, adjudged

and decreed that relator’s petition for writ of mandamus is hereby denied.

o O o

FILE COPY
[Federal Register Volume 74, Number 118 (Monday, June 22, 2009)]
[Notices]
[Page 29497]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-14521]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, P30 Competitive Revisions I.
    Date: August 6, 2009.
    Time: 8 a.m. to 11:30 a.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 
Wisconsin Avenue, Bethesda, MD 20814.
    Contact Person: Gail J. Bryant, Medical Officer, Resources and 
Training Review Branch, Division of Extramural Activities, National 
Cancer Institute, National Institutes of Health, 6116 Executive 
Boulevard, Room 8111, MSC 8328, Bethesda, MD 20852-8328, (301) 402-
0801, <a href="/cdn-cgi/l/email-protection#2a4d48191a5e6a444342044d455c"><span class="__cf_email__" data-cfemail="402722737034002e29286e272f36">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control; 93.701, ARRA Related Biomedical Research and Research 
Support Awards, National Institutes of Health, HHS)

    Dated: June 10, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-14521 Filed 6-19-09; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Exhibit 32.8
                                  CERTIFICATION
                       PURSUANT TO 18 U.S.C. SECTION 1350,
                    AS ADOPTED PURSUANT TO SECTION 906 OF THE
                           SARBANES-OXLEY ACT OF 2002


     The  undersigned  hereby  certify,  pursuant to 18 U.S.C.  Section 1350, as
adopted pursuant to Section 906 of the  Sarbanes-Oxley Act of 2002, that, to the
undersigned's  best knowledge and belief,  the Quarterly Report on Form 10-Q for
the Geodyne  Energy Income  Limited  Partnership  II-H ("Issuer") for the period
ending  March 31, 2007 as filed with the Securities and Exchange  Commission
on the date hereof (the "Report"):

      (a)   fully complies with the requirements of section 13(a) or 15(d) of
            the Securities Exchange Act of 1934; and
      (b)   the  information  contained in the Report  fairly  presents,  in all
            material respects, the financial condition and results of operations
            of the Issuer.

      Dated this 18th day of May, 2007.

                                    GEODYNE ENERGY INCOME LIMITED
                                    PARTNERSHIP II-H
                                    ("Issuer")

                                    //s// Dennis R. Neill
                                    -----------------------------------
                                    Dennis R. Neill
                                    President (Chief Executive Officer)

                                    //s// Craig D. Loseke
                                    -----------------------------------
                                    Craig D. Loseke
                                    Chief Accounting Officer
                                    (Chief Financial Officer)


      A signed  original of this written  statement  required by Section 906 has
been  furnished to Geodyne  Energy Income  Limited  Partnership II-H and will be
retained by Geodyne Energy Income Limited  Partnership II-H and furnished to the
Securities and Exchange Commission or its staff upon request.
# Fourth Court of Appeals

**San Antonio, Texas** 

August 6, 2014

No. 04

- 14

- 00554

- CV

IN RE LIFECELL CORPORATION

Original Mandamus Proceeding 1

ORDER

Sitting: Sandee Bryan Marion, Justice

Rebeca C. Martinez, Justice

Luz Elena D. Chapa, Justice

On August 5, 2014, relator LifeCell Corporation filed a petition for writ of mandamus

and an emergency motion for temporary relief. The court has considered the petition for writ of

mandamus and is of the opinion that relator is not entitled to the relie f sought. Accordingly, the

petition for writ of mandamus and emergency motion for temporary relief are DENIED. See

T EX

. R. A PP

. P . 52.8(a). The court’s opinion will issue at a later date.

It is so ORDERED on August 6 th , 2014.

_____________________________ Luz Elena D. Chapa, Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said

court on this 6 th day of August, 2014

.

_____________________________ Keith E. Hottle

Clerk of Court

1 This proceeding arises out of Cause No. 2014CI10718, styled LifeCell Corporation v. Novadaq Technologies, Inc.

and Novadaq Corp. , pending in the 166th Judicial District Court, Bexar County, Texas, the Honorable Peter A.

Sakai presiding.
Exhibit 10.1 Schedule 1.1A Commitments








Schedule 1.1A


Commitments


	
		
	Lender
	Commitment

	JPMorgan Chase Bank, N.A.
	$30,000,000.00

	PNC Bank, National Association
	$30,000,000.00

	Wells Fargo Bank, National Association
	$30,000,000.00

	Citibank, N.A.
	$20,000,000.00

	Comerica Bank
	$20,000,000.00

	The Huntington National Bank
	$20,000,000.00

	U.S. Bank National Association
	$20,000,000.00

	Regions Bank
	$15,000,000.00

	Texas Capital Bank, National Association
	$15,000,000.00

	Total Commitments
	$200,000,000
#     Adam Hartman, M.D.  

Pediatric Epilepsy; Clinical Epilepsy Research

adam.hartman@nih.gov

+1 301 496 9135

----

Dr. Adam Hartman is a Program Director in the Division of Clinical Research with a background in child neurology and epilepsy. Before joining NINDS, he was an Associate Professor of Neurology and Pediatrics at Johns Hopkins School of Medicine, with a joint appointment in the Johns Hopkins Bloomberg School of Public Health Department of Molecular Microbiology and Immunology. He also was Co-Director of the Neurosciences Intensive Care Nursery and Associate Program Director for the Child Neurology residency at Johns Hopkins. Dr. Hartman earned a bachelor's degree in Chemistry from Northwestern University and an MD from Northwestern University Medical School. During medical school, he was an HHMI-NIH Research Scholar at NIMH. After completing a residency in Pediatrics in the National Capital Uniformed Services Pediatric Residency Program, he served as a general pediatrician in the US Navy for five years (the last as Division Head of General Pediatrics at Naval Medical Center San Diego). He completed his residency in child neurology and a fellowship in clinical neurophysiology/pediatric epilepsy, both at Johns Hopkins. During his training, he studied the mechanism of the ketogenic diet at NINDS. As a faculty member at Johns Hopkins, his lab and clinical research on novel metabolism-based treatments for epilepsy was funded by NIH, the State of Maryland, and private sources. He also has published clinical research in child neurology, with an emphasis on the treatment of medically intractable epilepsy in childhood. His current interests include clinical trials in child neurology, epilepsy, and rare diseases. He is clinically active as a consultant in the Undiagnosed Diseases Program and other select protocols at the NIH Clinical Center.
----

Exhibit 32.2 

MPHASE TECHNOLGIES, INC. 

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350) 

In connection with the Quarterly Report of mPhaseTechnologies, Inc., a New Jersey corporation (the "Company"), on Form 10Q forthe quarter ended September 30, 2008 as amended by Amendment No. 1 on Form10Q/A, as filed with the Securities and Exchange Commission (the "Report"), I,Martin S Smiley, Chief Financial Officer of the Company certify, pursuant toSection 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350), that tohis knowledge: 

1. 

The Report fullycomplies with the requirements of Section 13(a) or 15(d) of the SecuritiesExchange Act of 1934; and 

2. 

The informationcontained in the Report fairly presents, in all material respects, the financialcondition and results of operations of the Company. 

/s/ Martin S. Smiley                        Martin S. Smiley Chief Financial Officer 

March 13, 2009 

 

----
NOT FINAL UNTIL TIME EXPIRES TO FILE REHEARING MOTION AND, IF FILED, DETERMINED

IN THE DISTRICT COURT OF APPEAL OF FLORIDA SECOND DISTRICT
In the Interest of M.A. and M.A., children. ) ___________________________________) ) K.A., ) ) Appellant, ) ) v. ) Case No. 2D18-2298 ) DEPARTMENT OF CHILDREN AND ) FAMILIES and GUARDIAN AD LITEM ) PROGRAM, ) ) Appellees. ) ___________________________________) Opinion filed October 17, 2018. Appeal from the Circuit Court for Lee County; Robert Branning, Judge. Karen H. Brouse, Blue Ridge, Georgia for Appellant. Meredith K. Hall of Children's Legal Services, Bradenton, for Appellee Department of Children and Families. Laura Lee, Tallahassee, and Rocco J. Carbone, III, St. Augustine, for Appellee Guardian Ad Litem Program. PER CURIAM.- 2 - Affirmed.
KELLY, KHOUZAM, and CRENSHAW, JJ., Concur.
<PAGE>


                                                                    EXHIBIT 99.3

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of ATS Medical, Inc. (the "Company") on
Form 10-Q for the period ended September 30, 2002 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Deborah K.
Chapman, Controller of the Company, certify, pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to
the best of my knowledge:

         1.       The Report fully complies with the requirements of Section
                  13(a) or 15(d) of the Securities Exchange Act of 1934; and

         2.       The information contained in the Report fairly presents, in
                  all material respects, the financial condition and results of
                  operations of the Company.



                                                /s/ Deborah K. Chapman
                                                --------------------------------
                                                Deborah K. Chapman
                                                Controller
                                                November 12, 2002
<TABLE> <S> <C>


<ARTICLE> 5
       
<S>                                            <C>                     <C>
<PERIOD-TYPE>                                3-MOS                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998             DEC-31-1997
<PERIOD-END>                               MAR-31-1998             MAR-31-1997
<CASH>                                       1,367,486                  18,830
<SECURITIES>                                         0                       0
<RECEIVABLES>                                3,478,283               1,820,807
<ALLOWANCES>                                         0                       0
<INVENTORY>                                     85,249                   7,392
<CURRENT-ASSETS>                             5,003,144               1,878,430
<PP&E>                                         574,939<F1>             284,774
<DEPRECIATION>                                       0                       0
<TOTAL-ASSETS>                              15,367,845               3,201,012
<CURRENT-LIABILITIES>                        5,799,621               1,735,453
<BONDS>                                      8,045,181<F2>           1,093,939         
<PREFERRED-MANDATORY>                          211,863<F3>                   0
<PREFERRED>                                          0                       0
<COMMON>                                       376,500                 376,500
<OTHER-SE>                                     935,180                 (7,978)
<TOTAL-LIABILITY-AND-EQUITY>                15,367,845               3,201,012
<SALES>                                      1,141,922                 784,674
<TOTAL-REVENUES>                                     0                       0
<CGS>                                          484,616                 338,383
<TOTAL-COSTS>                                1,045,787                 715,200
<OTHER-EXPENSES>                                     0                       0
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                              65,869                  10,210
<INCOME-PRETAX>                                 30,266                  59,264
<INCOME-TAX>                                     9,648                       0
<INCOME-CONTINUING>                                  0                       0
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                                    20,618                  59,264
<EPS-PRIMARY>                                      .01                     .15
<EPS-DILUTED>                                      .01                     .15
<FN>
<F1>Net of Depreciation
<F2>Long-Term Debt
<F3>Redeemable Warrants
</FN>
        




</TABLE>
#### Resat Keles, Appellant, v The Trustees of Columbia University in the City of New York et al., Respondents.

Submitted March 28, 2011;

decided May 10, 2011

Motion for leave to appeal dismissed upon the ground that the order sought to be appealed from does not finally determine the action within the meaning of the Constitution.
Exhibit 99.1

Section 906 Certification

Pursuant to Section 1350 of Title 18 of the United States Code, the undersigned hereby certifies that:

(1) I have reviewed the Quarterly Report on Form 10-Q of Inland Land Appreciation Fund, L.P. (the "Report") to which this statement is an Exhibit;

(2) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(3) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Inland Land Appreciation Fund, L.P.

 

By: Inland Real Estate Investment Corporation

       General Partner

/S/ Brenda G. Gujral                                   

Name: Brenda G. Gujral

Title: President of the General Partner and

          Principal Executive Officer of Inland Land Appreciation Fund, L.P

Date: May 12, 2003
**EXHIBIT 31.2** **CHIEF    FINANCIAL OFFICER CERTIFICATION**     I, J. Clarke Gray, certify that:     1. I have reviewed this Amendment No. 1 to the Annual    Report on    Form 10-K/A    of BKF Capital Group, Inc.;     2. Based on my knowledge, this report does not contain any    untrue statement of a material fact or omit to state a material    fact necessary to make the statements made, in light of the    circumstances under which such statements were made, not    misleading with respect to the period covered by this report;     3. The registrant’s other certifying officer and I are    responsible for establishing and maintaining disclosure controls    and procedures (as defined in Exchange Act    Rules 13a-15(e)    and    15d-15(e))    and internal control over financial reporting (as defined in    Exchange Act    Rules 13a-15(f)    and    15d-15(f))    for the registrant and have:     a) Designed such disclosure controls and procedures, or    caused such disclosure controls and procedures to be designed    under our supervision, to ensure that material information    relating to the registrant, including its consolidated    subsidiaries, is made known to us by others within those    entities, particularly during the period in which this report in    being prepared;     b) Designed such internal control over financial reporting,    or caused such internal control over financial reporting to be    designed under our supervision, to provide reasonable assurance    regarding the reliability of financial reporting and the    preparation of financial statements for external purposes in    accordance with generally accepted accounting principles;     c) Evaluated the effectiveness of the registrant’s    disclosure controls and procedures and presented in this report    our conclusions about the effectiveness of the disclosures    controls and procedures, as of the end of he period covered by    this report based on such evaluation; and     d) Disclosed in this report any change in the    registrant’s internal control over financial reporting that    occurred during the registrant’s most recent fiscal quarter    that has materially affected, or is reasonably likely to    materially affect, the registrant’s internal control over    financial reporting; and     4. The registrant’s other certifying officer and I    have disclosed, based on our most recent evaluation of internal    control over financial reporting, to the registrant’s    auditors and the audit committee of registrant’s board of    directors (or persons performing the equivalent functions):     a) All significant deficiencies and material weaknesses in    the design or operation of internal controls over financial    reporting which are reasonably likely to adversely affect the    registrant’s ability to record, process, summarize and    report financial information; and     b) Any fraud, whether or not material, that involves    management or other employees who have a significant role in the    registrant’s internal control over financial reporting. /s/  J.    CLARKE GRAY    J. Clarke Gray    Chief Financial Officer     Date: April 15, 2008